Department of Artificial Cardiac Pacemaker Stimulation and Cardiac Rehabilitation, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
ESC Heart Fail. 2023 Aug;10(4):2751-2753. doi: 10.1002/ehf2.14429. Epub 2023 Jun 12.
Although cardiac resynchronization therapy (CRT) improves functional capacity in heart failure patients, a blunted heart rate (HR) response remains after treatment. So we aimed to evaluate the feasibility of the physiological pacing rate (PPR) in CRT patients.
A cohort of 30 clinical mildly symptomatic CRT patients underwent the six-minute walk test (6MWT). During the 6MWT, HR, blood pressure, and maximum walking distance were assessed. The measurements were obtained in a pre to post manner, with CRT at nominal settings and with the physiological phase (CRT PPR), in which HR was increased by 10% above the maximum HR achieved previously. The CRT cohort also comprised a matched control group (CRT CG). In the CRT CG, the 6MWT was repeated after the standard evaluation with no PPR. The evaluations were blinded for patients and for the 6MWT evaluator.
During the 6MWT, CRT PPR led to an increase in walking distance of 40.5 m (9.2%; P < 0.0001) when compared with baseline trial. Additionally, CRT PPR increased the maximum walking distance compared with CRT CG 479.3 ± 68.9 m vs. 420.3 ± 44.8 m, respectively, P = 0.001. In the CRT CG, CRT PPR increased the variation in walking distance, compared with baseline trials, respectively 2.40 ± 3.8% vs. 9.25 ± 7.0%, P = 0.007.
In mildly symptomatic CRT patients PPR is feasible, leading to improvements in functional capacity. In this regard, the efficacy of PPR must be confirmed by controlled randomized trials.
尽管心脏再同步治疗(CRT)可改善心力衰竭患者的功能能力,但治疗后心率(HR)反应仍然迟钝。因此,我们旨在评估 CRT 患者生理起搏率(PPR)的可行性。
一组 30 名临床轻度症状性 CRT 患者接受了 6 分钟步行测试(6MWT)。在 6MWT 期间,评估 HR、血压和最大步行距离。测量是在 CRT 处于标称设置和生理阶段(CRT PPR)时从前到后进行的,其中 HR 比以前达到的最大 HR 增加 10%。CRT 队列还包括一个匹配的对照组(CRT CG)。在 CRT CG 中,在没有 PPR 的标准评估后重复进行 6MWT。评估对患者和 6MWT 评估者都是盲目的。
在 6MWT 期间,与基线试验相比,CRT PPR 使步行距离增加了 40.5m(9.2%;P<0.0001)。此外,与 CRT CG 相比,CRT PPR 增加了最大步行距离,分别为 479.3±68.9m 与 420.3±44.8m,P=0.001。在 CRT CG 中,与基线试验相比,CRT PPR 分别使步行距离的变化增加了 2.40±3.8%与 9.25±7.0%,P=0.007。
在轻度症状性 CRT 患者中,PPR 是可行的,可改善功能能力。在这方面,必须通过对照随机试验来证实 PPR 的疗效。